Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Depreciation & Amortization: 2016-2024

  • Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization rose 17.44% to $4.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.2 million, marking a year-over-year increase of 39.27%. This contributed to the annual value of $710,000 for FY2024, which is 21.37% down from last year.
  • According to the latest figures from Q4 2024, Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization is $4.8 million, which was up 17.44% from $4.1 million recorded in Q4 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $4.8 million during Q4 2024, and registered a low of $2.3 million during Q4 2021.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $4.1 million (2023), whereas its average is $4.0 million.
  • Data for Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY soared of 39.73% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $2.3 million in 2021, then skyrocketed by 39.73% to $3.2 million in 2022, then increased by 28.65% to $4.1 million in 2023, then increased by 17.44% to $4.8 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $4.8 million for Q4 2024, versus $4.1 million for Q4 2023 and $3.2 million for Q4 2022.